BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Russell FM, Balloch A, Tang ML, Carapetis JR, Licciardi P, Nelson J, Jenney AW, Tikoduadua L, Waqatakirewa L, Pryor J. Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine. Vaccine. 2009;27:5685-5691. [PMID: 19616498 DOI: 10.1016/j.vaccine.2009.06.098] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Russell FM, Carapetis JR, Satzke C, Tikoduadua L, Waqatakirewa L, Chandra R, Seduadua A, Oftadeh S, Cheung YB, Gilbert GL, Mulholland EK. Pneumococcal nasopharyngeal carriage following reduced doses of a 7-valent pneumococcal conjugate vaccine and a 23-valent pneumococcal polysaccharide vaccine booster. Clin Vaccine Immunol 2010;17:1970-6. [PMID: 20943882 DOI: 10.1128/CVI.00117-10] [Cited by in Crossref: 51] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
2 Russell FM, Balloch A, Licciardi PV, Carapetis JR, Tikoduadua L, Waqatakirewa L, Cheung YB, Mulholland EK, Tang ML. Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months. Vaccine 2011;29:4499-506. [PMID: 21539882 DOI: 10.1016/j.vaccine.2011.04.038] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
3 Russell FM, Mulholland K. Pneumococcal vaccines in Nepal. Lancet Infect Dis 2019;19:115-6. [PMID: 30635254 DOI: 10.1016/S1473-3099(18)30608-X] [Reference Citation Analysis]
4 Temple B, Toan NT, Uyen DY, Balloch A, Bright K, Cheung YB, Licciardi P, Nguyen CD, Phuong NTM, Satzke C, Smith-Vaughan H, Vu TQH, Huu TN, Mulholland EK. Evaluation of different infant vaccination schedules incorporating pneumococcal vaccination (The Vietnam Pneumococcal Project): protocol of a randomised controlled trial. BMJ Open 2018;8:e019795. [PMID: 29884695 DOI: 10.1136/bmjopen-2017-019795] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
5 Scott P, Rutjes AW, Bermetz L, Robert N, Scott S, Lourenço T, Egger M, Low N. Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: Systematic review and meta-analysis. Vaccine 2011;29:9711-21. [DOI: 10.1016/j.vaccine.2011.07.042] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 5.0] [Reference Citation Analysis]
6 Fritzell B, Fletcher MA. Pneumococcal polysaccharide–protein (CRM 197 ) conjugate vaccines, 7- or 9-valent, in the 2 + 1 schedule. Expert Review of Vaccines 2014;10:263-90. [DOI: 10.1586/erv.11.11] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
7 Jackowska T, Pluta J. Routine infant immunization with the 7- and 13-valent pneumococcal conjugate vaccines: current perspective on reduced-dosage regimens. Arch Med Sci 2012;8:542-8. [PMID: 22852013 DOI: 10.5114/aoms.2012.29410] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Lindholm DE, Licciardi PV, Ratu FT, Kim Mulholland E, Nguyen CD, Russell FM. Predictors of antibody persistence to the 7-valent pneumococcal conjugate vaccine in healthy Fijian infants at 12 months of age. Vaccine 2020;38:5095-9. [PMID: 32580918 DOI: 10.1016/j.vaccine.2020.06.025] [Reference Citation Analysis]
9 Choe YJ, Blatt DB, Lee HJ, Choi EH. Associations between geographic region and immune response variations to pneumococcal conjugate vaccines in clinical trials: A systematic review and meta-analysis. Int J Infect Dis 2020;92:261-8. [PMID: 32147023 DOI: 10.1016/j.ijid.2019.12.021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
10 Lemaître C, Ferroni A, Doit C, Vu-thien H, Glorion C, Raymond J, Mary P, Wicart P, Bingen E, Ilharreborde B, Lorrot M. Pediatric osteoarticular infections caused by Streptococcus pneumoniae before and after the introduction of the heptavalent pneumococcal conjugate vaccine. Eur J Clin Microbiol Infect Dis 2012;31:2773-81. [DOI: 10.1007/s10096-012-1627-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
11 Javati S, Masiria G, Elizah A, Matlam JP, Ford R, Richmond PC, Lehmann D, Pomat WS, van den Biggelaar AHJ. An observational study of the reactogenicity and immunogenicity of 13-valent pneumococcal conjugate vaccine in women of childbearing age in Papua New Guinea. Pneumonia (Nathan) 2020;12:13. [PMID: 33292822 DOI: 10.1186/s41479-020-00076-1] [Reference Citation Analysis]
12 Ota MO, Roca A, Bottomley C, Hill PC, Egere U, Greenwood B, Adegbola RA. Pneumococcal antibody concentrations of subjects in communities fully or partially vaccinated with a seven-valent pneumococcal conjugate vaccine. PLoS One 2012;7:e42997. [PMID: 22916192 DOI: 10.1371/journal.pone.0042997] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
13 Mackenzie GA, Bottomley C, van Hoek AJ, Jeffries D, Ota M, Zaman SM, Greenwood B, Cutts F. Efficacy of different pneumococcal conjugate vaccine schedules against pneumonia, hospitalisation, and mortality: re-analysis of a randomised trial in the Gambia. Vaccine 2014;32:2493-500. [PMID: 24631086 DOI: 10.1016/j.vaccine.2014.02.081] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
14 Givon-lavi N, Greenberg D, Dagan R. Immunogenicity of Alternative Regimens of the Conjugated 7-Valent Pneumococcal Vaccine: A Randomized Controlled Trial. Pediatric Infectious Disease Journal 2010;29:756-62. [DOI: 10.1097/inf.0b013e3181d99345] [Cited by in Crossref: 41] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
15 Toh ZQ, Quang C, Tooma JA, Garland SM, Mulholland K, Licciardi PV. Australia's Role in Pneumococcal and Human Papillomavirus Vaccine Evaluation in Asia-Pacific. Vaccines (Basel) 2021;9:921. [PMID: 34452046 DOI: 10.3390/vaccines9080921] [Reference Citation Analysis]
16 Nicholls TR, Leach AJ, Morris PS. The short-term impact of each primary dose of pneumococcal conjugate vaccine on nasopharyngeal carriage: Systematic review and meta-analyses of randomised controlled trials. Vaccine 2016;34:703-13. [PMID: 26742947 DOI: 10.1016/j.vaccine.2015.12.048] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
17 Rodgers GL, Esposito S, Principi N, Gutierrez-Brito M, Diez-Domingo J, Pollard AJ, Snape MD, Martinón-Torres F, Gruber WC, Patterson S, Thompson A, Gurtman A, Paradiso P, Scott DA. Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule. Vaccine 2013;31:4765-74. [PMID: 23965217 DOI: 10.1016/j.vaccine.2013.08.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
18 Ota MO, Akinsola A, Townend J, Antonio M, Enwere G, Nsekpong D, Bojang A, Saaka M, Burton RL, Zaman A, Goldblatt D, Adegbola RA. The immunogenicity and impact on nasopharyngeal carriage of fewer doses of conjugate pneumococcal vaccine immunization schedule. Vaccine 2011;29:2999-3007. [PMID: 21320549 DOI: 10.1016/j.vaccine.2011.01.098] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
19 Boelsen LK, Dunne EM, Mika M, Eggers S, Nguyen CD, Ratu FT, Russell FM, Mulholland EK, Hilty M, Satzke C. The association between pneumococcal vaccination, ethnicity, and the nasopharyngeal microbiota of children in Fiji. Microbiome 2019;7:106. [PMID: 31311598 DOI: 10.1186/s40168-019-0716-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
20 Russell FM, Carapetis JR, Balloch A, Licciardi PV, Jenney AW, Tikoduadua L, Waqatakirewa L, Pryor J, Nelson J, Byrnes GB, Cheung YB, Tang ML, Mulholland EK. Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial. Vaccine 2010;28:3341-9. [PMID: 20206670 DOI: 10.1016/j.vaccine.2010.02.087] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 5.8] [Reference Citation Analysis]
21 Balloch A, Licciardi PV, Tang MLK. Serotype-Specific Anti-Pneumococcal IgG and Immune Competence: Critical Differences in Interpretation Criteria When Different Methods are Used. J Clin Immunol 2013;33:335-41. [DOI: 10.1007/s10875-012-9806-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
22 Rückinger S, van der Linden M, Reinert RR, von Kries R. Efficacy of 7-valent pneumococcal conjugate vaccination in Germany: An analysis using the indirect cohort method. Vaccine 2010;28:5012-6. [PMID: 20546832 DOI: 10.1016/j.vaccine.2010.05.021] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
23 Grimprel E, Laudat F, Patterson S, Baker S, Sidhu M, Gruber W, Emini E, Scott D. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose to children immunized with PCV7 as infants. Vaccine 2011;29:9675-83. [DOI: 10.1016/j.vaccine.2011.10.012] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
24 Park DE, Johnson TS, Nonyane BA, Chandir S, Conklin L, Fleming-Dutra KE, Loo JD, Goldblatt D, Whitney CG, O'Brien KL, Deloria Knoll M. The differential impact of coadministered vaccines, geographic region, vaccine product and other covariates on pneumococcal conjugate vaccine immunogenicity. Pediatr Infect Dis J 2014;33 Suppl 2:S130-9. [PMID: 24336055 DOI: 10.1097/INF.0000000000000081] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
25 Whitney CG, Goldblatt D, O'Brien KL. Dosing schedules for pneumococcal conjugate vaccine: considerations for policy makers. Pediatr Infect Dis J 2014;33 Suppl 2:S172-81. [PMID: 24336059 DOI: 10.1097/INF.0000000000000076] [Cited by in Crossref: 54] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
26 Rückinger S, Dagan R, Albers L, Schönberger K, von Kries R. Immunogenicity of pneumococcal conjugate vaccines in infants after two or three primary vaccinations: A systematic review and meta-analysis. Vaccine 2011;29:9600-6. [DOI: 10.1016/j.vaccine.2011.09.011] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
27 Scott P, Ott F, Egger M, Low N. Completeness of reporting in randomized controlled trials of 3 vaccines: a review of adherence to the CONSORT checklist. Pediatr Infect Dis J 2012;31:1286-94. [PMID: 22935870 DOI: 10.1097/INF.0b013e31827032bb] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
28 Dendle C, Stuart RL, Mulley WR, Holdsworth SR. Pneumococcal vaccination in adult solid organ transplant recipients: A review of current evidence. Vaccine 2018;36:6253-61. [PMID: 30217523 DOI: 10.1016/j.vaccine.2018.08.069] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
29 Russell FM, Licciardi PV, Balloch A, Biaukula V, Tikoduadua L, Carapetis JR, Nelson J, Jenney AW, Waqatakirewa L, Colquhoun S, Cheung YB, Tang ML, Mulholland EK. Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy. Vaccine 2010;28:3086-94. [PMID: 20199764 DOI: 10.1016/j.vaccine.2010.02.065] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
30 Temple B, Griffiths UK, Mulholland EK, Ratu FT, Tikoduadua L, Russell FM. The cost of outpatient pneumonia in children <5 years of age in Fiji. Trop Med Int Health 2012;17:197-203. [PMID: 22008519 DOI: 10.1111/j.1365-3156.2011.02897.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
31 Tyo KR, Rosen MM, Zeng W, Yap M, Pwee KH, Ang LW, Shepard DS. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines. Vaccine 2011;29:6686-94. [PMID: 21745516 DOI: 10.1016/j.vaccine.2011.06.091] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 4.3] [Reference Citation Analysis]
32 Licciardi PV, Balloch A, Russell FM, Mulholland EK, Tang ML. Antibodies to serotype 9V exhibit novel serogroup cross-reactivity following infant pneumococcal immunization. Vaccine 2010;28:3793-800. [PMID: 20362199 DOI: 10.1016/j.vaccine.2010.03.033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
33 Marès Bermúdez J, van Esso Arbolave D, Arístegui Fernández J, Ruiz Contreras J, González Hachero J, Merino Moína M, Barrio Corrales F, Álvarez García F, Cilleruelo Ortega M, Ortigosa del Castillo L, Moreno Pérez D. Calendario de vacunaciones de la Asociación Española de Pediatría: recomendaciones 2010. Anales de Pediatría 2010;72:433.e1-433.e17. [DOI: 10.1016/j.anpedi.2010.02.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
34 Conklin L, Loo JD, Kirk J, Fleming-Dutra KE, Deloria Knoll M, Park DE, Goldblatt D, O'Brien KL, Whitney CG. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children. Pediatr Infect Dis J 2014;33 Suppl 2:S109-18. [PMID: 24336053 DOI: 10.1097/INF.0000000000000078] [Cited by in Crossref: 60] [Cited by in F6Publishing: 35] [Article Influence: 8.6] [Reference Citation Analysis]
35 Russell FM, Carapetis JR, Burton RL, Lin J, Licciardi PV, Balloch A, Tikoduadua L, Waqatakirewa L, Cheung YB, Tang ML. Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age. Vaccine. 2011;29:535-544. [PMID: 21044669 DOI: 10.1016/j.vaccine.2010.10.046] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
36 Licciardi PV, Balloch A, Russell FM, Nahm MH, Mulholland K, Tang ML. Pneumococcal glycoconjugate vaccines produce antibody responses that strongly correlate with function. Nat Rev Drug Discov 2011;10:393. [PMID: 21532568 DOI: 10.1038/nrd3012-c1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
37 Klugman KP, Dagan R, Malley R, Whitney CG. Pneumococcal Conjugate Vaccine and Pneumococcal Common Protein Vaccines. Plotkin's Vaccines. Elsevier; 2018. pp. 773-815.e18. [DOI: 10.1016/b978-0-323-35761-6.00045-6] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
38 Boelsen LK, Dunne EM, Lamb KE, Bright K, Cheung YB, Tikoduadua L, Russell FM, Mulholland EK, Licciardi PV, Satzke C. Long-term impact of pneumococcal polysaccharide vaccination on nasopharyngeal carriage in children previously vaccinated with various pneumococcal conjugate vaccine regimes. Vaccine 2015;33:5708-14. [PMID: 26232540 DOI: 10.1016/j.vaccine.2015.07.059] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
39 Deloria Knoll M, Park DE, Johnson TS, Chandir S, Nonyane BA, Conklin L, Fleming-Dutra KE, Loo JD, Goldblatt D, Whitney CG, O'Brien KL. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity. Pediatr Infect Dis J 2014;33 Suppl 2:S119-29. [PMID: 24336054 DOI: 10.1097/INF.0000000000000079] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 5.1] [Reference Citation Analysis]
40 Tamura K, Matsubara K, Ishiwada N, Nishi J, Ohnishi H, Suga S, Ihara T, Chang B, Akeda Y, Oishi K. Hyporesponsiveness to the infecting serotype after vaccination of children with seven-valent pneumococcal conjugate vaccine following invasive pneumococcal disease. Vaccine 2014;32:1444-50. [DOI: 10.1016/j.vaccine.2014.01.031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
41 Tashani M, Jayasinghe S, Harboe ZB, Rashid H, Booy R. Potential carrier priming effect in Australian infants after 7-valent pneumococcal conjugate vaccine introduction. World J Clin Pediatr 2016; 5(3): 311-318 [PMID: 27610348 DOI: 10.5409/wjcp.v5.i3.311] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
42 Meerveld-Eggink A, de Weerdt O, van Velzen-Blad H, Biesma DH, Rijkers GT. Response to conjugate pneumococcal and Haemophilus influenzae type b vaccines in asplenic patients. Vaccine 2011;29:675-80. [PMID: 21115060 DOI: 10.1016/j.vaccine.2010.11.034] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
43 Dunne EM, Manning J, Russell FM, Robins-Browne RM, Mulholland EK, Satzke C. Effect of pneumococcal vaccination on nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Staphylococcus aureus in Fijian children. J Clin Microbiol 2012;50:1034-8. [PMID: 22170924 DOI: 10.1128/JCM.06589-11] [Cited by in Crossref: 46] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]
44 Licciardi PV, Russell FM, Balloch A, Burton RL, Nahm MH, Gilbert G, Tang ML, Mulholland EK. Impaired serotype-specific immune function following pneumococcal vaccination in infants with prior carriage. Vaccine 2014;32:2321-7. [PMID: 24613524 DOI: 10.1016/j.vaccine.2014.02.064] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
45 Dagan R, Ben-shimol S, Simell B, Greenberg D, Porat N, Käyhty H, Givon-lavi N. A toddler PCV booster dose following 3 infancy priming doses increases circulating serotype-specific IGG levels but does not increase protection against carriage. Vaccine 2018;36:2774-82. [DOI: 10.1016/j.vaccine.2018.04.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
46 Licciardi PV, Balloch A, Russell FM, Burton RL, Lin J, Nahm MH, Mulholland EK, Tang ML. Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses. J Allergy Clin Immunol 2012;129:794-800.e2. [PMID: 22305678 DOI: 10.1016/j.jaci.2011.11.043] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
47 Arguedas A, Soley C, Abdelnour A. Prevenar experience. Vaccine 2011;29:C26-34. [DOI: 10.1016/j.vaccine.2011.06.104] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
48 Dendle C, Stuart RL, Polkinghorne KR, Balloch A, Kanellis J, Ling J, Kummrow M, Moore C, Thursky K, Buttery J, Mulholland K, Gan PY, Holdsworth S, Mulley WR. Seroresponses and safety of 13-valent pneumococcal conjugate vaccination in kidney transplant recipients. Transpl Infect Dis 2018;20:e12866. [PMID: 29512234 DOI: 10.1111/tid.12866] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
49 Hoe E, Boelsen LK, Toh ZQ, Sun GW, Koo GC, Balloch A, Marimla R, Dunne EM, Tikoduadua L, Russell FM, Satzke C, Mulholland EK, Licciardi PV. Reduced IL-17A Secretion Is Associated with High Levels of Pneumococcal Nasopharyngeal Carriage in Fijian Children. PLoS One 2015;10:e0129199. [PMID: 26069966 DOI: 10.1371/journal.pone.0129199] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
50 Chang B, Nariai A, Sekizuka T, Akeda Y, Kuroda M, Oishi K, Ohnishi M. Capsule Switching and Antimicrobial Resistance Acquired during Repeated Streptococcus pneumoniae Pneumonia Episodes. J Clin Microbiol 2015;53:3318-24. [PMID: 26269621 DOI: 10.1128/JCM.01222-15] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
51 Silfverdal SA, Flodmark C, Rombo L, Tansey SP, Sidhu M, Trammel J, Emini EA, Gruber WC, Scott DA, Gurtman A. 13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): A phase 3, open-label trial. Vaccine 2013;31:1284-92. [DOI: 10.1016/j.vaccine.2012.12.066] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]